000293782 001__ 293782
000293782 005__ 20250826104555.0
000293782 0247_ $$2doi$$a10.1016/j.critrevonc.2024.104523
000293782 0247_ $$2pmid$$apmid:39326645
000293782 0247_ $$2ISSN$$a0737-9587
000293782 0247_ $$2ISSN$$a1040-8428
000293782 0247_ $$2ISSN$$a1879-0461
000293782 037__ $$aDKFZ-2024-01940
000293782 041__ $$aEnglish
000293782 082__ $$a610
000293782 1001_ $$aSprokkerieft, Julia$$b0
000293782 245__ $$aOutcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review.
000293782 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2024
000293782 3367_ $$2DRIVER$$aarticle
000293782 3367_ $$2DataCite$$aOutput Types/Journal article
000293782 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730895239_24895$$xReview Article
000293782 3367_ $$2BibTeX$$aARTICLE
000293782 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293782 3367_ $$00$$2EndNote$$aJournal Article
000293782 500__ $$aVolume 204, December 2024, 104523
000293782 520__ $$aRenal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for treatment of RCC in adults, but its effects in children and young adults with RCC remains unclear. Due to the histological and biological differences between children and adults, it is difficult to extrapolate knowledge on treatments from the adult to the pediatric and young adult setting. This paper summarizes the clinical characteristics and outcomes of patients with RCC who were treated with axitinib, with the aim to gain insight in the clinical efficacy of this compound in this young patient group.
000293782 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000293782 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293782 650_7 $$2Other$$aPediatric
000293782 650_7 $$2Other$$aaxitinib
000293782 650_7 $$2Other$$arenal cell carcinoma
000293782 650_7 $$2Other$$ayoung adult
000293782 7001_ $$avan der Beek, Justine N$$b1
000293782 7001_ $$aSpreafico, Filippo$$b2
000293782 7001_ $$0P:(DE-He78)16933397bb16ab9603a3f27b4b314f81$$aSelle, Barbara$$b3
000293782 7001_ $$aChowdhury, Tanzina$$b4
000293782 7001_ $$aGraf, Norbert$$b5
000293782 7001_ $$aVerschuur, Arnauld C$$b6
000293782 7001_ $$aDandis, Rana$$b7
000293782 7001_ $$aBex, Axel$$b8
000293782 7001_ $$aGeller, James I$$b9
000293782 7001_ $$aTytgat, Godelieve A M$$b10
000293782 7001_ $$avan den Heuvel-Eibrink, Marry M$$b11
000293782 773__ $$0PERI:(DE-600)2025731-4$$a10.1016/j.critrevonc.2024.104523$$gp. 104523 -$$p104523$$tCritical reviews in oncology, hematology$$v204$$x0737-9587$$y2024
000293782 8564_ $$uhttps://inrepo02.dkfz.de/record/293782/files/1-s2.0-S104084282400266X-main.pdf
000293782 8564_ $$uhttps://inrepo02.dkfz.de/record/293782/files/1-s2.0-S104084282400266X-main.pdf?subformat=pdfa$$xpdfa
000293782 909CO $$ooai:inrepo02.dkfz.de:293782$$pVDB
000293782 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)16933397bb16ab9603a3f27b4b314f81$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000293782 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000293782 9141_ $$y2024
000293782 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000293782 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCRIT REV ONCOL HEMAT : 2022$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000293782 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCRIT REV ONCOL HEMAT : 2022$$d2023-10-24
000293782 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000293782 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000293782 980__ $$ajournal
000293782 980__ $$aVDB
000293782 980__ $$aI:(DE-He78)B062-20160331
000293782 980__ $$aI:(DE-He78)HD01-20160331
000293782 980__ $$aUNRESTRICTED